Skin Cancers | Clinical

Lifileucel TIL Therapy Demonstrates Durable Responses in Pretreated Advanced Melanoma

April 11, 2021

In the phase 2 C-144-01 trial, patients had durable responses to treatment with the tumor-infiltrating lymphocyte lifileucel after more than 28 months of follow-up.

Initial Treatment With Tebentafusp Show Significant OS Improvement in Metastatic Uveal Melanoma

April 10, 2021

In patient with metastatic uveal melanoma, frontline treatment with tebentafusp achieved significant and clinically meaningful improvement in overall survival, according to data from the phase 3 IMCgp100-202 trial.

Experts Contemplate Realistic Treatment Goals Using Hedgehog Inhibitors in Basal Cell Carcinoma

March 26, 2021

Hedgehog inhibitors are becoming more widely used for Basal cell carcinoma. Two experts, Shailender Bhatia, MD and Paul T. Nghiem, MD, PhD discussed the reality of hedgehog inhibitor use in practice during a virtual Targeted Oncology Case-Based Roundtable event.

Tilsotolimod Plus Ipilimumab Shows Suboptimal Responses in Anti–PD-1 Refractory Advanced Melanoma

March 19, 2021

The combination of tilsotolimod and ipilimumab demonstrated a low objective response rate in patients with anti–PD-1–refractory advanced melanoma, missing the coprimary end point of the phase 3 ILLUMINATE-301 trial.

Nemvaleukin for Mucosal Melanoma Granted FDA’s Orphan Drug Status

March 12, 2021

Nemvaleukin alfa, an interleukin-2 variant immunotherapy for the treatment of mucosal melanoma, has been granted orphan drug designation by the FDA,

FDA’s Orphan Drug Status Granted to LNS8801 for Metastatic Uveal Melanoma

March 10, 2021

The FDA granted Orphan Drug Designation to the novel GPER agonist, LNS8801, for the treatment of patients with metastatic uveal melanoma.

Cavrotolimod Granted Orphan Drug Designation for Merkel Cell Carcinoma

March 05, 2021

The FDA granted Orphan Drug Designation to cavrotolimod, for the treatment of patients with Merkel cell carcinoma, announced Exicure, Inc, in a press release.

Tebentafusp Granted FDA Breakthrough Therapy Designation for Unresectable or Metastatic Uveal Melanoma

February 19, 2021

The FDA has granted a Breakthrough Therapy Designation to tebentafusp for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma .

FDA Approves Cemiplimab for Locally Advanced and Metastatic Basal Cell Carcinoma

February 09, 2021

The FDA has approved cemiplimab-rwlc, the PD-1 inhibitor, for the treatment of patients with advanced basal cell carcinoma previously treated with a hedgehog pathway inhibitor or for whom a hedgehog inhibitor is not appropriate.

Rabinowits Analyzes the Use of Anti–PD-1 Therapy in cSCC

February 01, 2021

During a Targeted Oncology Case-Based Peer Perspectives event, Guilherme Rabinowits, MD, medical oncologist/hematologist, Miami Cancer Institute, discussed the case of 69-year-old patients with cutaneous squamous cell carcinoma.